22246-12-4, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 22246-12-4, molcular formula is C10H11NO2, introducing its new discovery.
Vitronectin receptor antagonists
Compounds of formula (I) are disclosed, wherein: A is a fibrinogen antagonist template; W is a linking moiety of the form –(CHRg)a –U–(CHRg)b –V–; Q1, Q2, Q3 and Q4 are independently N or C–Ry, provided that no more than one Q1, Q2, Q3 and Q4 is N; R’ is H or C1-6 alkyl, C3-7 cycloalkyl-C0-6 -alkyl or Ar–C0-6 alkyl; Rg is H or C1-6 alkyl, Het-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl or Ar–C0-6 alkyl; Rk is Rg, –C(O)Rg or –C(O)ORg Ri is H, C1-6 alkyl, Het-C0-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl, Ar–C0-6 alkyl, Het-C0-6 alkyl–U’–C1-6 alkyl, C3-7 cycloalkyl-C0-6 alkyl–U’–C1-6 alkyl or Ar–C0-6 alkyl–U’–C1-6 alkyl; Ry is H, halo, –ORg, –SRg, –CN, –NRg Rk, –NO2, –CF3, CF3 S(O)r, –CO2 Rg, –CORg or –CONRg2, or C1-6 alkyl optionally substituted by halo, –ORg, –SRg, –CN, –NR8 R”, –NO2, –CF3, R’S(O)3 –, –CO2 Rg, –CORg or –CONRg2 ; U and V are absent or CO, CRg2, C(=CRg2), S(O)c, O, NRg, CRg ORg, CRg (ORk)CRg2, CRg7 CRg (ORk), C(O)CRg2, CRg2 C(O), CONRi, NRi CO, OC(O), C(O)O, OC(S), C(S)NRg, NR8 C(S), S(O2 NRg, NRg S(O)2 N=N, NRg NRg, NRg CRg2, NRg CRg2, CRg2 O, OCRg2, CRg =CRg, C?C, Ar or Het; a is 0, 1 or 2; c is 0, 1 or 2; r is 0, 1 or 2; and u is 0 or 1; or pharmaceutically acceptable salts thereof, which are vitronectin receptor antagonists useful in the treatment of osteoporosis. STR1
Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 22246-12-4, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 22246-12-4
Reference£º
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem